Search

Displaying results 1021 - 1030 of 1279 in total
  1. Drug

    LLL-3348

    go.drugbank.com/drugs/DB05771
    Experimental

    The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.

  2. Drug

    Dexketoprofen

    go.drugbank.com/drugs/DB09214
    ApprovedInvestigationalWithdrawn

    Dexketoprofen is a non-steroidal anti-inflammatory drug. It is available in the various countries in Europe, Asia and Latin America. It has analgesic, antipyretic and anti-inflammatory properties .

    Mixtures: TİO-DEXİREN 25MG/ 4 MG FİLM KAPLI TABLET, 20 ADET, TİO-DEXİREN 25MG/ 8 MG FİLM KAPLI TABLET, 14 ADET
  3. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom ...

  4. Drug

    Cupric sulfate

    go.drugbank.com/drugs/DB06778
    Approved

    Cupric sulfate is a salt created by treating cupric oxide with sulfuric acid. This forms as large, bright blue crystals containing five molecules of water (CuSO4∙5H2O) and is also known as blue vitriol. The anhydrous salt is created by h...

    Mixtures: Tl-hem 150, Tl-hem 150
  5. Drug

    Glyburide

    go.drugbank.com/drugs/DB01016
    ApprovedInvestigational

    Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin se...

    Mixtures: SIL-NORBORAL ® 5/500 MG, SIL - NORBORAL ® 5 MG / 1000 MG
  6. Drug

    Lenacapavir

    go.drugbank.com/drugs/DB15673
    ApprovedInvestigational

    HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens. Lenacapavir is a first-in-class ...

  7. Drug

    Olmesartan

    go.drugbank.com/drugs/DB00275
    ApprovedInvestigational

    However, this does not prevent the formation of all angiotensin II within the body. … The angiotensin II receptor blocker (ARB) family of drugs unique in that it blocks all angiotensin II activity, regardless of where or how it was synthesized.

  8. Drug

    Elbasvir

    go.drugbank.com/drugs/DB11574
    Approved

    HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, affecting 72% of all chronic HCV patients. … of HCV infection are associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of hepatocellular carcinoma, and reduced all-cause

  9. Drug

    Boceprevir

    go.drugbank.com/drugs/DB08873
    ApprovedWithdrawn

    HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. … of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause

  10. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    In addition, nirsevimab was developed as a single-dose treatment for all infants experiencing their first RSV season, whereas palivizumab requires five monthly doses to cover an RSV season. … [A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies.